Major Funding Announcement by Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) has achieved a significant milestone by announcing the final closure of its exercise of outstanding preferred investment options, successfully securing approximately $25.2 million in gross proceeds. This strategic move is part of their ongoing efforts to innovate and expand within the medical device industry.
Details of the Investment Offering
The recent funding initiative involved a total of 13,989,115 shares of common stock being made available through a structured three-tranche offering. During the first tranche, holders of the preferred investment options exercised their rights to acquire 12,064,627 shares at exercise prices ranging from $1.50 to $2.13 each. This exercise was conducted during the first closing period and was facilitated by Microbot's proactive engagement in the market.
Subsequent Tranche Closures
Following the initial closing, the second tranche saw an additional exercise of 600,000 shares at an exercise price of $2.10 each. The third and final tranche concluded with the exercise of 1,324,488 shares, also priced at $2.10. Each exercise not only provided immediate cash flow to the company but also involved issuing new unregistered short-term series J preferred investment options aiming to enhance the financing capacity of Microbot.
Use of Proceeds from the Offering
The total gross proceeds raised are anticipated to bolster the financial resources for Microbot Medical's ongoing projects, including further development and commercialization efforts centered around the LIBERTY® Robotic System. This advanced medical technology is designed to revolutionize endovascular procedures, enhancing precision and safety in medical settings.
Future Growth and Innovation Plans
Microbot aims to utilize these funds strategically for various objectives, including potential acquisitions that align with its technological advancements, expansion opportunities, and ongoing regulatory activities. The company is also focused on exploring additional applications that can arise from its existing intellectual property portfolio, emphasizing its commitment to innovation and excellence in the healthcare sector. This focused strategy positions Microbot to not only maintain but also enhance its competitive edge in the rapidly evolving medical field.
The Role of Investment Partners
The successful closing of the offering would not have been possible without the expertise of H.C. Wainwright & Co., who acted as the exclusive placement agent. Their guidance has been instrumental in facilitating a smooth funding process, enabling Microbot to successfully navigate the complexities of capital raises in today's challenging market environment.
Microbot’s Vision for the Future
With a robust intellectual property portfolio and a dedicated focus on innovation, Microbot Medical is poised for substantial growth. The company’s LIBERTY® Endovascular Robotic System represents a groundbreaking advancement in medical technology, marking a new era for minimally invasive surgical procedures. Microbot’s ongoing commitment to research and development ensures that they will continue to lead the charge in providing advanced healthcare solutions.
Frequently Asked Questions
What is the total amount raised by Microbot Medical?
Microbot Medical has successfully raised approximately $25.2 million from its recent offering of preferred investment options.
What will the funds be used for?
The funds will be utilized for the ongoing development and commercialization of the LIBERTY® Robotic System, potential acquisitions, and general corporate purposes.
Who acted as the placement agent for this offering?
H.C. Wainwright & Co. acted as the exclusive placement agent for Microbot Medical’s offering.
What is the LIBERTY® Robotic System?
The LIBERTY® Robotic System is a cutting-edge medical device designed for endovascular procedures, focusing on precision and safety.
What future plans does Microbot have following this funding?
Microbot plans to explore further innovation opportunities, potential acquisitions, and expand its applications based on its existing technology portfolio.
